4//SEC Filing
FEBBO WILLIAM J 4
Accession 0001213900-24-085379
CIK 0001769804other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 1:17 PM ET
Size
9.2 KB
Accession
0001213900-24-085379
Insider Transaction Report
Form 4
Augmedix, Inc.AUGX
FEBBO WILLIAM J
Director
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2024-10-02−50,000→ 0 totalExercise: $2.80Exp: 2032-03-27→ Common Stock (50,000 underlying) - Disposition to Issuer
Common Stock
2024-10-02$2.35/sh−162,583$382,070→ 0 total
Footnotes (4)
- [F1]Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings.
- [F2]Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
- [F3]Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option.
- [F4]The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023.
Documents
Issuer
Augmedix, Inc.
CIK 0001769804
Entity typeother
Related Parties
1- filerCIK 0001413987
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 1:17 PM ET
- Size
- 9.2 KB